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Abstract
Background: In intensive care units (ICU) octogenarians become a routine patients group with aggravated
therapeutic and diagnostic decision-making. Due to increased mortality and a reduced quality of life in this
high-risk population, medical decision-making a fortiori requires an optimum of risk stratification. Recently, the
VIP-1 trial prospectively observed that the clinical frailty scale (CFS) performed well in ICU patients in overall-survival and
short-term outcome prediction. However, it is known that healthcare systems differ in the 21 countries contributing to
the VIP-1 trial. Hence, our main focus was to investigate whether the CFS is usable for risk stratification in octogenarians
admitted to diversified and high tech German ICUs.
Methods: This multicentre prospective cohort study analyses very old patients admitted to 20 German ICUs as a
sub-analysis of the VIP-1 trial. Three hundred and eight patients of 80 years of age or older admitted consecutively to
participating ICUs. CFS, cause of admission, APACHE II, SAPS II and SOFA scores, use of ICU resources and ICU- and
30-day mortality were recorded. Multivariate logistic regression analysis was used to identify factors associated with
30-day mortality.
Results: Patients had a median age of 84 [IQR 82–87] years and a mean CFS of 4.75 (± 1.6 standard-deviation) points.
More than half of the patients (53.6%) were classified as frail (CFS≥ 5). ICU-mortality was 17.3% and 30-day mortality
was 31.2%. The cause of admission (planned vs. unplanned), (OR 5.74) and the CFS (OR 1.44 per point increase) were
independent predictors of 30-day survival.
Conclusions: The CFS is an easy determinable valuable tool for prediction of 30-day ICU survival in octogenarians,
thus, it may facilitate decision-making for intensive care givers in Germany.
Trial registration: The VIP-1 study was retrospectively registered on ClinicalTrials.gov (ID: NCT03134807) on May 1, 2017.
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Background
Very old patients (age ≥ 80 years) now comprise approxi-
mately one fourth of all intensive care unit (ICU) admis-
sions in the United States and similarly in Europe,
receive much more intensive medical treatment than in
the past, and progressively survive even fatal critical ill-
nesses [1, 2]. However, in view of enormous personal ef-
forts of intensive care givers and increased economic
costs due to prolonged and complicated ICU stays of oc-
togenarians, proportionality of costs and resource usage
came in focus [2] with two main aspects: First, emer-
gency triage process must be optimised and simplified to
facilitate ICU admission for very old patients [3, 4]. Sec-
ond, more scientific and clinical interest must be applied
on all aspects of geriatric medicine to adapt existing
risk-stratification data to daily clinical scenarios [5, 6].
In this context, a 9-point Clinical Frailty Scale (CFS)
as an advancement of the Canadian 7-point CFS has
been developed [7]. Recently, the prospective, observa-
tional, European-ICU-network based VIP-1 study dem-
onstrated that frailty is a significant factor reducing
30-day survival and that the 9-point CFS is an appropri-
ate tool to assess this effect [4]. The rationale behind sci-
entific efforts in this field is explained by the very
complex nature of circumscribing frailty to other specific
medical problems [8]. Consecutively, whereas physical
frailty is a measurable clinical phenotype of increased
vulnerability for developing adverse outcomes (e.g. dis-
ability and/or mortality) when exposed to a stressor, it
is highly difficult to explain the current frailty status in
an abbreviated and objective manner to another
medical-professional.
As the largest study investigating the value of pread-
mission CFS in elderlies admitted to ICUs, the VIP-1
study was one of the first large studies highlighting the
impact of assessing CFS as a herald for outcome in very
old ICU patients [4]. The advanced 9-point CFS, mea-
sured at a rapid diagnostic glance, showed even more ro-
bust outcome-foreshowing value compared to routinely
used ICU indices like SOFA or APACHE-II score in
VIP-1 [4].
ICUs from 21 European countries and 3 Non-Europe
countries participated in the VIP-1 study [4]. The par-
ticipating countries represent a broad range of different
health care systems and philosophies, and less than 10%
of included patients came from Germany. The recent
Organisation for Economic Co-operation and Develop-
ment (OECD) health report emphasized the differences
in health status and life expectancy in the participating
countries, leading to varying challenges [9]. These fac-
tors most likely affect case mixes and intensity of treat-
ment provided in ICUs of the different countries
participating in the VIP-1 trial. Indeed, VIP-1 showed re-
gional differences in the frequency of frail patients
admitted to ICUs. Consequently, the conclusions drawn
by the multi-national VIP-1 study might not be transfer-
able to the individual health care situation of each par-
ticipating country. In this current study, we undertook a
multicentre sub-analysis of the German VIP-1 cohort
and aimed to test if the predictive value of CFS is still
robust on a national level in very diversified and
high-tech German ICUs.
Methods
Study sample
This analysis is a sub-analysis of the 20 German ICUs
participating in the prospectively realised observational
multicentre European VIP-1 study (Fig. 1) [4]. The aim
of the study was to investigate whether the CFS is us-
able for risk stratification in octogenarians admitted to
diversified and high tech German ICUs. The VIP-1
study was coordinated by the Health Services Resource
and Outcome (HSRO) section of the European Society
of Intensive Care Medicine (ESICM) and was regis-
tered on ClinicalTrials.gov (ID: NCT03134807; first
posted on May 1st 2017 after recruitment completed).
All patients at least 80 years of age admitted to the
participating ICUs for any cause were eligible for
documentation after giving written informed consent
(by themselves or responsible advisor). Data from not
more than 20 consecutive patients per ICU were
collected.
Ethical approval was obtained from each study side
(Additional file 1: Ethic committees). Patients were re-
cruited between October 2016 and February 2017.
Data collection and scoring systems
Initial Simplified Acute Physiology Score II (SAPS II),
Acute Physiology And Chronic Health Evaluation II
(APACHE II) and Sequential Organ Failure Assessment
(SOFA) scores were calculated by treating physicians
within 24 h after admission as reported previously
[10–12]. Length of stay (LOS) was recorded in hours,
allowing calculation of LOS in 24-h periods rather than
in calendar days. It was recorded whether patients were
subjected to invasive or non-invasive ventilation, vaso-
active drugs were administered or renal replacement
therapy was applied during their ICU stay. However, the
duration of those intensive therapies was not recorded.
The database was located on a secure server in Aarhus
University, Denmark.
Frailty
Frailty was defined according to the Clinical Frailty Scale
(CFS). The CFS is an easy and intuitive determinable
categorisation tool based on simple visual descriptions
[7]. The CFS divides patients into 9 classes from very fit
(CFS = 1) to terminally ill (CFS = 9). The status of the
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patients before hospital admission was obtained from
the patients or their relatives.
Statistical analyses
Statistical analyses were performed using SPSS (IBM
Corp. Released 2013. IBM SPSS Statistics for Windows,
Version 22.0. Armonk, NY, USA). For statistical ana-
lyses, patients were stratified according to their admis-
sion status (planned vs. unplanned). The patients with
unplanned admission were further divided into the fol-
lowing three groups: acute medical, acute surgery and
trauma. Patients were followed for 30 days after ICU ad-
mission. Baseline patient characteristics, treatment and
outcomes were compared between two frailty groups
based on the CFS: not-frail (CFS 1–4) and frail (CFS 5–9)
as used in previous publications [6].
Additionally, for characterisation of patients according
to 30-day survival and according to the type of admis-
sion, frailty status was defined as not frail (CFS 1–3),
pre-frail (CFS 4) and frail (CFS 5–9) [4]. Frailty was also
analysed using the whole scale as ordinal data. For con-
tinuous variables, normally distributed data is given in
mean ± standard deviation and compared by student’s
t-test. Non-normally distributed data is shown as me-
dian with inter-quartile-range and compared by Mann-
Whitney-U-Test or Kruskal-Wallis-Test as appropriate.
Categorical variables were described by counts and per-
centages. Differences between groups were calculated
by Chi-square test. The impact of age, gender, APACHE
II, SAPS II, Sofa-score, type of admission (planned vs.
unplanned, acute medical vs. acute surgery, acute surgery
vs. trauma and acute medical vs. trauma) and frailty on
30-day mortality was estimated using logistic regression
analyses. Variables with a p-value below 0.10 in univariate
logistic regression analysis were included in the multivari-
ate logistic regression model to estimate the adjusted im-
pact of frailty on 30-day mortality. P-values < 0.05 were
considered significant.
Fig. 1 Participating ICUs. Participating ICUs are marked. The number of enclosed patients is indicated for each participating ICU
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Results
In this sub-analysis of the European VIP-1 study cohort,
a total number of 308 patients of 80 years of age or older
admitted to 20 German ICUs were analysed. Participating
ICUs collected data from 3 to 20 patients (Fig. 1).
Median age was 84 [IQR 82–87] years and 50% of the
patients were male. Median LOS in the ICU was 3.1
[IQR 1.1–8.1] days. ICU-mortality was 17.3% and 30-day
mortality was 31.2% (Table 1). Out of the analysed ICU
patients, 31.5% had planned admissions due to post sur-
gery care. The other patients were admitted due to acute
medical reasons (52.6%), trauma (10.7%) or acute sur-
gery (5.2%) as shown in Table 1 and Fig. 2. Respiratory
and/or circulatory failure was the most frequent cause
for admission. Use of life sustaining treatments is shown
in Table 1. In 26.6% of the patients none of the ICU pro-
cedures were recorded. Frailty according to the CFS
could be determined for all patients.
Frail patients are characterized by frailty score ≥ 5 and
not frail patients by a frailty score ≤ 4. Data are pre-
sented as median and interquartile range [IQR] or fre-
quency and percentages (n, %). ICU: Intensive Care Unit.
CFS: Clinical Frailty Score ranging from 1 (not frail) to 9
(terminally ill).
Planned admitted patients had a lower CFS com-
pared to acute admitted patients and showed a lower
ICU- and 30-day mortality (Fig. 2, Table 2). Data are
presented as median and interquartile range [IQR] or
frequency and percentages (n, %). ICU: Intensive Care
Unit. CFS: Clinical Frailty Score ranging from 1 (not frail)
to 9 (terminally ill).
For further evaluation of the impact of frailty, patients
were divided into two groups according to their frailty
status as depicted in Table 1. Frail patients showed
higher values for organ failure and ICU treatment was
more often withhold or withdrawn. However, there was
no significant difference between frail and non-frail pa-
tients with regard to the APACHE-II and SAPS-II
scores. ICU mortality and 30-day mortality were signifi-
cantly higher for frail patients compared to non-frail pa-
tients (Table 1 and Fig. 2). Patients surviving 30 days
after ICU admission were less frail, stayed shorter in
ICU, got less invasive treatment and treatment was less
often withheld or withdrawn (Table 3). Data are pre-
sented as interquartile range [IQR] or absolute numbers
and percentages (n, %). ICU: Intensive Care Unit. CFS:
Clinical Frailty Score ranging from 1 (not frail) to 9 (ter-
minally ill).
Univariate regression analysis showed that frailty mea-
sured by the CFS as well as APACHE II, SAPS II and
SOFA scores and the cause of admission (unplanned vs.
planned) were associated with higher 30-day mortality.
Table 1 Patient characteristics according to the frailty status
Frailty status Overall Not frail (CFS 1–4) Frail (CFS 5–9) p-value
Number of admissions 308 (100%) 143 (46.4%) 165 (53.6%)
Age 84 [82–87] 82 [81–86] 85 [82–88] < 0.001
Male 164 (50%) 79 (55.2%) 75 (45.5%) 0.09
APACHE II 18 [12–26] 15 [12–25] 19 [12–26] 0.18
SAPS II 39 [29.5–51] 37 [29–48] 42 [30–55] 0.17
SOFA Score 6 [3–10] 6 [3–9] 7 [4–10] 0.016
Cause of admission
Acute medical 162 (52.6%) 58 (40.6%) 104 (63%) < 0.001
Acute surgery 16 (5.2%) 8 (5.6%) 8 (4.8%) 0.77
Trauma 33 (10.7%) 14 (9.8%) 19 (11.5%) 0.63
Elective surgery 97 (31.5%) 63 (44.1%) 34 (20.6%) < 0.001
ICU length of stay (days) 3.1 [1.1–8.1] 2.9 [1–7] 3.4 [1.4–9.5] 0.21
Use of life sustaining treatments
Non-invasive ventilation 104 (33.8%) 48 (33.6%) 56 (33.9%) 0.95
Mechanical ventilation 141 (45.8%) 59 (41.3%) 82 (49.7%) 0.14
Vasoactive drugs 189 (61.4%) 82 (57.3%) 107 (64.8%) 0.18
Renal replacement therapy 59 (19.2%) 26 (18.2%) 33 (20%) 0.69
Treatment withheld 41 (13.3%) 11 (7.7%) 30 (18.2%) 0.01
Treatment withdrawn 36 (11.7%) 10 (7%) 26 (15.8%) 0.02
ICU mortality 53 (17.3%) 16 (11.3%) 37 (22.4%) 0.01
30-day mortality 84 (31.2%) 23 (18.4%) 61 (42.4%) < 0.001
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Fig. 2 Association of the Clinical Frailty Scale with 30-day mortality in acute admitted patients. Distribution of frailty in acute and elective admitted
Patients (a). Association of frailty with 30-day mortality (b). Patients were divided into three groups according to their frailty status: fit (CFS 1–3), pre-frail
(CFS 4) and frail (CFS 5–9). CFS: Clinical Frailty Score ranging from 1 (not frail) to 9 (terminally ill)
Table 2 Patient characteristics according to the cause of admission
Admission unplannd vs. planned Unplanned Planned p-value
Cause of admission Acute medical Acute surgery Trauma Elective surgery Elective vs acute
Sample size 162 (52.6%) 16 (5.2%) 33 (10.7%) 97 (31.5%)
Age 84 [82–86] 83 [81–89] 86 [83–90] 83 [81–87] 0.33
Male 82 (50.6%) 12 (75%) 13 (39.4%) 47 (48.5%) 0.71
APACHE II 20 [15–27] 18 [14–18] 18 [13–24] 14 [10–19] 0.001
SAPS II 42 [34–53] 46 [42–46] 31 [23–46] 35 [26–49] 0.03
SOFA Score 8 [4–10] 11 [6–13] 6 [4–9] 4 [3–7] < 0.001
Frailty status
Fit (CFS 1–3) 30 (18.5%) 7 (43.8%) 8 (24.2%) 28 (28.9%) 0.15
Pre-frail (CFS 4) 28 (17.3%) 1 (6.3%) 6 (18.2%) 35 (36.1%) < 0.001
Frail (CFS 5–9) 104 (64.2%) 8 (50%) 19 (57.6%) 34 (35.1%) < 0.001
ICU length of stay (days) 5 [2.0–10.5] 6.2 [2.1–17.6] 3 [1.3–6.8] 1.4 [1–3.5] < 0.001
Use of life sustaining treatments
Non-invasive ventilation 63 (38.9%) 6 (37.5%) 10 (30.3%) 25 (25.8%) 0.04
Mechanical ventilation 75 (46.3%) 13 (81.3%) 20 (60.6%) 33 (34%) 0.005
Vasoactive drugs 110 (67.9%) 15 (93.8%) 20 (60.6%) 44 (45.4%) < 0.001
Renal replacement therapy 41 (25.3%) 4 (25%) 1 (3%) 13 (13.4%) 0.08
Treatment withheld 29 (17.9%) 3 (18.8%) 9 (27.3%) 0 (0%) < 0.001
Treatment withdrawn 27 (16.7%) 3 (18.8%) 4 (12.1%) 2 (2.1%) < 0.001
ICU mortality 39 (24.1%) 4 (25%) 6 (18.2%) 4 (4.2%) < 0.001
30-day mortality 61 (41.8%) 6 (50%) 10 (38.5%) 7 (8.2%) < 0.001
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In a multivariate regression analysis the cause of admis-
sion was the strongest predictor for 30-day mortality
(OR 5.74) after adjusting for other covariates. Thus,
mortality was 5.74 times higher in acute admitted pa-
tients compared to elective admitted patients. Moreover,
the CFS independently predicted 30-day mortality in the
multivariate regression analyses (OR 1.44). Thus, for
each point increase of the CFS, mortality increased by
1.4 times. However, the APACHE II, SAPS II and SOFA
scores failed to predict 30-day mortality in a multivariate
regression analysis (Table 4).
Impact of the different factors on 30-day mortality in a
univariate model is presented in the left part of the table.
Factors with a p-value below 0.10 in a univariate logistic
regression analysis were included into the multivariate
model shown in the right part of the table. Impact of the
factors on 30-day mortality is presented as Odd’s Ratio
(OR) in the univariate model or as adjusted Odd’s Ratio
(AOR) in the multivariate model respectively, and 95%
Confidence Interval (95% CI). CFS: Clinical Frailty Score
ranging from 1 (not frail) to 9 (terminally ill).
Discussion
This multicentre analysis of the German VIP-1 cohort
[4] focussing on a large cohort of more than 300 very
old patients admitted to 20 German ICUs showed that
frailty measured by the 9-point CFS [4] is a valuable pre-
dictor of ICU- and 30-day mortality for very old patients
admitted to highly diversified and high-tech German
ICUs. These findings complement the recent analyses of
the multi-national, prospective European VIP-1 cohort [4].
Table 3 Patient characteristics according to the survival status
30 day survival status Survivors Nonsurvivors p value
Number of admissions 185 (68.8%) 84 (31.2%)
Age 83 [81–86] 85 [81–88] 0.06
Male 85 (45.9%) 47 (56%) 0.13
APACHE II 17 [12–23] 25 [18–32] < 0.001
SAPS II 37 [29–50] 48 [39–61] 0.001
SOFA Score 6 [3–9] 8 [5–11] < 0.001
Frailty status
Fit (CFS 1–3) 52 (28.1%) 12 (14.3%) 0.014
Pre-frail (CFS 4) 50 (27%) 11 (13%) 0.011
Frail (CFS 5–9) 83 (44.9%) 61 (72.6%) < 0.001
Cause of admission
Acute medical 85 (45.9%) 61 (72.6%) < 0.001
Acute surgery 6 (3.2%) 6 (7.1%) 0.15
Trauma 16 (8.6%) 10 (11.9%) 0.4
Elective surgery 78 (42.2%) 7 (8.3%) < 0.001
ICU length of stay (days) 2.7 [1–8] 5.2 [2.2–9.8] 0.012
Use of life sustaining treatments
Non-invasive Ventilation 69 (37.3%) 28 (33.3%) 0.53
Mechanical ventilation 74 (40%) 58 (69%) < 0.001
Vasoactive drugs 107 (57.8%) 66 (78.6%) 0.001
Renal replacement therapy 31 (16.8%) 27 (32.1%) 0.004
Treatment withheld 8 (4.3%) 32 (38.1%) < 0.001
Treatment withdrawn 1 (0.5%) 34 (40.5%) < 0.001
ICU mortality 0 (0%) 53 (63.1%) < 0.001
Table 4 Survival analyses: Univariate and multivariate logistic regression analyses
Parameter Univariate predictor Multivariable predictor model
OR 95% CI p value AOR 95% CI p value
Age (per year increase) 1.069 [0.999;1.114] 0.053 1.040 [0.920; 1.177] 0.531
Male 0.669 [0.398; 1.124] 0.13
APACHE II (per point increase) 1.101 [1.046; 1.158] <0.001 1.053 [0.982; 1.129] 0.149
SAPS II (per point increase) 1.024 [1.006; 1.043] 0.01 1.007 [0.973; 1.043] 0.672
SOFA Score (per point increase) 1.150 [1.075; 1.231] <0.001 1.072 [0.914; 1.259] 0.392
Type of admission
Acute vs. elective 8.019 [3.507; 18.333] <0.001 5.744 [1.186; 27.811] 0.030
Acute medical vs acute surgery 0.718 [0.221; 2.332] 0.581
Acute surgery vs. trauma 1.600 [0.402; 6.361] 0.504
Acute medical vs. trauma 1.148 [0.488; 2.702] 0.752
Frailty
Frailty (per point increase) 1.410 [1.187; 1.675] <0.001 1.437 [1.052; 1.964] 0.023
Frail (CFS 5-9) 3.259 [1.861; 5.708] <0.001
Pre-frail (CFS 4) 0.407 [0.200; 0.829] 0.013
Fit (CFS 1-3) 0.426 [0.214; 0.850] 0.015
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In previous publications, conducted mainly in single
centres, huge differences of ICU survival rates among
octogenarians ranging from 14 to 46% have been de-
scribed [13, 14]. This divergence can most likely be ex-
plained by case mix differences. Thus, the multi-national
European VIP-1 study showed that in central, northern
and eastern Europe a higher percentage of the admitted
patients were frailer than in southern and western Euro-
pean countries [4]. This finding is also reflected by the re-
cent OECD health report pointing out differences in
health care systems in the OECD countries [9]. Our ana-
lysis of very old patients in German ICUs showed an ICU
mortality of 17.3% and a 30-day mortality of 31.2% similar
to the multi-national VIP-1 cohort with 22.1 and 32.4%
and to a Canadian cohort with 21.8 and 35% [15], re-
spectively. However, despite high mortality rates, it is
difficult to identify patients at risk among that vulner-
able cohort since commonly used scoring systems for
prediction of ICU outcome were developed for younger
cohorts and are not reliable for use in the very old [16].
Thus, in contrast to the results of the multi-national
VIP-1 cohort, APACHE II, SAPS II and the SOFA score
failed to predict 30-day mortality in a multivariate re-
gression analysis on our multicentre cohort of very old
patients in German ICUs. Recently, it was suggested
that frailty is correlated with mortality in very old pa-
tients and that quantification of frailty might predict
the outcome of very old patients admitted to ICUs.
Frailty is defined as a condition of clinical vulnerability
associated with age dependent reduction of physio-
logical reserves [17]. Different scores for the assessment
of frailty were developed and their ability for the pre-
diction of adverse outcomes including decline in functional
performance, prolonged length of stay, institutionalisation,
and mortality in geriatric patient collectives was confirmed
[4, 18–22]. Using the previously reported 9-point CFS [4],
we could show that increased frailty was independently as-
sociated with intra-ICU and 30-day mortality in a multicen-
tre cohort of very old patients admitted to German ICUs.
Thus, our data confirmed the observations of previous
studies from Europe [4] and America [23] and proofed the
usability of the CFS for risk stratification of octogenarians
in German ICUs. The only parameter that was stronger as-
sociated with 30-day mortality than the frailty status was
the type of admission (planned vs. unplanned). That obser-
vation might be caused by a selection bias since our ana-
lyses revealed that electively admitted patients were less
frail and showed lower APACHE II, SAPS II and SOFA
scores. Furthermore, health status of patients selected for
elective surgery could be optimized prior to ICU admission.
In contrast to the analysis of the multi-national European
VIP-1 cohort [4], our sub-analysis of the German VIP-1 co-
hort revealed no independent impact of age, gender or
the SOFA score on 30-day mortality in a multivariate
regression analysis. This important difference between
the multi-national VIP-1 cohort comprising patients
treated in different healthcare systems with diverging
philosophies and financial resources and our more
homogeneous German sub-cohort is most likely caused
by the above mentioned inhomogeneity of the multi-
national cohort. Thus, in contrast to the analysis of the
multi-national VIP-1 cohort, our analysis among very
old patients admitted to German ICUs showed that in
octogenarians and nonagenarians not chronologic age
but the bioenergetics state, stratified by the CFS, is a
strong predictor of mortality.
The strengths of our study include its prospective
multicentre character and the relatively high number of
included patients. Time dependent confounders were
minimized by limiting recruiting time to 8 months, thus
time dependent confounders could be minimalized.
However, this study has limitations. No data on the
proportion of included patients in relation to all ICU ad-
missions nor data on patients that were not admitted to
ICU due to triage decisions were recorded. For the sake
of feasibility, neither long-term survival nor the func-
tional status of the patients after ICU discharge were
assessed. The used 9-point frailty scale is subjective with
potentially high inter-rater variability. Nonetheless, in
the context of acute ICU admission of vulnerable pa-
tients it is likely to be more feasible and easier to access
than more objective scoring systems.
Conclusion
In conclusion, the CFS is an easy determinable valuable
tool for the prediction of mortality in very old patients,
thus it can facilitate decision making for intensive care
givers in Germany.
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